Gold prices tick higher on fresh U.S. tariff threats, Fed rate cut hopes
RANCHO CUCAMONGA, CA—Petersen Floyd F., a director at Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), recently sold 500 shares of the company’s common stock. The transactions took place on April 1, 2025, with shares sold at a weighted average price of $28.3805, resulting in a total sale value of $14,190. The sale comes as the stock trades near its 52-week low of $25.89, down approximately 25% year-to-date, despite the company maintaining strong financial health according to InvestingPro analysis.
The sale was conducted under a Rule 10b5-1 trading plan that Floyd had adopted on November 26, 2024. Following this transaction, Floyd retains 73,909 shares of Amphastar Pharmaceuticals. With a P/E ratio of 8.38 and current market analysis suggesting undervaluation, InvestingPro subscribers can access detailed valuation metrics and 8 additional key insights about AMPH’s investment potential.
The sale was executed in multiple transactions with prices ranging from $28.28 to $28.86 per share. Floyd has committed to providing detailed information regarding the number of shares sold at each price upon request.
In other recent news, Amphastar Pharmaceuticals reported its fourth-quarter 2024 earnings, which fell short of analyst expectations. The company posted an earnings per share (EPS) of $0.92, missing the forecasted $0.97, while revenue reached $186.5 million, below the anticipated $192.69 million. This performance marks a deviation from previous quarters where Amphastar generally met or exceeded expectations. Piper Sandler subsequently adjusted its price target for Amphastar, lowering it to $32.00 from $36.00, while maintaining a Neutral rating on the stock.
Amphastar’s management has indicated that revenue for 2025 is expected to remain flat compared to 2024, due to diminishing margins on certain generic products. The company faces challenges in maintaining its gross margins, which decreased to 46.5% from 54% year-over-year. Despite these challenges, Amphastar is optimistic about returning to double-digit growth in 2026 and is focusing on launching new products, with potential approvals for four key products in 2025.
Investors are keeping a close watch on the potential market entry of AMP-002, a first-to-market generic injectable product, which could significantly impact revenue and EBITDA growth. Regulatory approval for AMP-002 is anticipated in late 2025 or early 2026. Amphastar is also expanding its manufacturing capacity and increasing R&D spending to support future growth, signaling a strategic shift towards its branded and proprietary portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.